David M Goldenberg
Overview
Explore the profile of David M Goldenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
318
Citations
9009
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rugo H, Tolaney S, Loirat D, Punie K, Bardia A, Hurvitz S, et al.
NPJ Breast Cancer
. 2024 Jun;
10(1):41.
PMID: 38844800
No abstract available.
2.
Cardillo T, Zalath M, Arrojo R, Sharkey R, Govindan S, Chang C, et al.
Oncotarget
. 2024 Feb;
15:144-158.
PMID: 38386805
Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed antibody conjugated with the topoisomerase I inhibitory drug, SN-38, via a proprietary hydrolysable linker. SG has received United States...
3.
Rugo H, Tolaney S, Loirat D, Punie K, Bardia A, Hurvitz S, et al.
NPJ Breast Cancer
. 2022 Aug;
8(1):98.
PMID: 36038616
Sacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate with an SN-38 payload. In the ASCENT study, patients with metastatic triple-negative breast cancer (mTNBC) relapsed/refractory to ≥2 prior chemotherapy regimens (≥1...
4.
Goldenberg D, Sharkey R, Govindan S, Cardillo T
Mol Cancer Ther
. 2022 Jan;
21(1):237.
PMID: 34996865
No abstract available.
5.
Bardia A, Hurvitz S, Tolaney S, Loirat D, Punie K, Oliveira M, et al.
N Engl J Med
. 2021 Apr;
384(16):1529-1541.
PMID: 33882206
Background: Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which...
6.
Wallace D, Figueras F, Wegener W, Goldenberg D
Ann Rheum Dis
. 2021 Feb;
80(7):954-955.
PMID: 33619162
No abstract available.
7.
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Ansquer C, Rauscher A, Frampas E, et al.
J Nucl Med
. 2021 Feb;
62(9):1221-1227.
PMID: 33547213
Pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the Ga-labeled IMP288 peptide for immuno-PET have been optimized in a first-in-humans study performed on medullary...
8.
Pichon B, Rousseau C, Blanc-Lapierre A, Delpon G, Ferrer L, Libois V, et al.
Biomedicines
. 2020 Dec;
8(12).
PMID: 33260610
(1) Background: Stereotactic body radiotherapy (SBRT) for vertebral metastases (VM) allows the delivery of high radiation doses to tumors while sparing the spinal cord. We report a new approach to...
9.
Cardillo T, Rossi D, Zalath M, Liu D, Arrojo R, Sharkey R, et al.
Oncotarget
. 2020 Nov;
11(43):3849-3862.
PMID: 33196706
Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of a humanized anti-Trop-2 IgG antibody conjugated a hydrolysable linker to SN-38, the topoisomerase I-inhibitory active component of irinotecan. We investigated whether...
10.
Elekonawo F, de Gooyer J, Bos D, Goldenberg D, Boerman O, Brosens L, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32316388
Image-guided surgery can aid in achieving complete tumor resection. The development and assessment of tumor-targeted imaging probes for near-infrared fluorescence image-guided surgery relies mainly on preclinical models, but the translation...